Orchid Pharma Community
NSEI:ORCHPHARMA Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
Community Investing Ideas
AN
Consensus Narrative from 3 Analysts
US Partnership For Enmetazobactam Will Unlock Significant Market Opportunities
Key Takeaways EU GMP certification could enable Orchid Pharma's European market expansion and boost future revenue. Investments in Orchid AMS targeting antimicrobial resistance are expected to enhance future profitability.
View narrative₹1.00k
FV
29.5% undervalued intrinsic discount31.67%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
about 4 hours ago author updated this narrative